Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | HTR2B | P41595 | 3/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.47 |
| ▸ | SMO | Q99835 | 1/20 | 0.47 |
| ▸ | APOB | P04114 | 5/20 | 0.47 |
| ▸ | MTTP | P55157 | 5/20 | 0.47 |
| ▸ | UGCG | Q16739 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795248 | 0.90 | SMO (0.47) | HTR2CHTR2AHTR2BSMOAPOB | |
| SCHEMBL6799425 | 0.89 | MTTP (0.49) | HTR2CHTR2AHTR2BSMOAPOB | |
| SCHEMBL6796059 | 0.87 | SMO (0.58) | HTR2CHTR2AHTR2BNR3C1SMO | |
| SCHEMBL6805247 | 0.81 | MTTP (0.49) | SMOAPOBMTTPRAB9AGAA | |
| SCHEMBL6256948 | 0.81 | CXCR1 (0.54) | SMOAPOBMTTPRAB9AGAA | |
| SCHEMBL6793635 | 0.81 | MTTP (0.51) | NR3C1SMOAPOBMTTPUGCG | |
| SCHEMBL6794847 | 0.81 | MTTP (0.52) | NR3C1SMOAPOBMTTPUGCG | |
| SCHEMBL6788361 | 0.80 | SMO (0.56) | HTR2CHTR2AHTR2BNR3C1SMO | |
| SCHEMBL6794869 | 0.80 | SMO (0.56) | HTR2CHTR2AHTR2BNR3C1SMO | |
| SCHEMBL7083646 | 0.79 | GAA (0.49) | HTR2CHTR2AHTR2BRAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | HTR2C 1124/4885HTR2A 659/4885HTR2B 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.